$2995 | Single User
$5990 | Site License
$8985 | Enterprise License

Human Drugs For Veterinary Use - Current Trends and Future Commercial Prospects for Crossover Drugs

Published by CBR Pharma Insights: 01 May 2016 | 19908 | In Stock

Introduction

Human Drugs For Veterinary Use - Current Trends and Future Commercial Prospects for Crossover Drugs

Summary

GBI Research's latest report, "Human Drugs For Veterinary Use - Current Trends and Future Commercial Prospects for Crossover Drugs", discusses global commercial trends and prospects for human medicines applied in the veterinary setting, also called crossover drugs. A wide range of human drugs continue to be applied in the veterinary space due to a lack of approved animal therapies, convenience and the rising costs of veterinary research.

This new report provides insights into Extra-label Drug Use (ELDU), its application in the veterinary setting and other guidelines and regulations followed by professionals in the animal health industry. Through a series of in-depth case studies this report provides insights into the rationale for the transition of several human drugs to the veterinary setting as well as disease overviews, competing treatments, manufacturer information, dosage forms, cost of therapy and other insightful marketing information. Our new study also identifies and explores important drivers and restraints of the crossover drugs market.

Information leveraged from our robust industry-leading database shows a diverse range of marketed human drugs being used in companion animals especially cats, dogs and horses. Our new report includes detailed profiles of key animal health companies with diverse portfolios of crossover drugs as well as strategies being employed by competitors in this market to leverage human therapies into the veterinary space. Additionally, we identify emerging companies marketing various crossover drugs across a range of therapy areas.

GBI Research conducted extensive research in order to provide a comprehensive view of the current trends and commercial prospects for crossover drugs. This new report adds to our unique portfolio of trusted industry analyses that enable our clients to assess the most promising commercial areas in the market and exploit key business opportunities.

Scope

What regulations need to be followed when prescribing human drugs off-label to pets and food-producing animals?

What are the main factors driving the prescription of human medicines in animals?

Marketed human drugs commonly used in companion animals

- What are the differences in indication between the human and veterinary setting?

- What are the dosage and side effects of those specific drugs in animals?

- Are there any existing and approved veterinary therapies for the same indication? Why is the human drug preferred over the approved animal drug?

- What are the key drivers and barriers that affect ELDU of human drugs in animals?

- What is currently restricting the crossover drugs market?

- What are the key animal health companies with prominent crossover drug portfolios?

Explore recent financial performance, crossover drugs brands, and the number of species supported through their animal health product portfolio

Identify emerging companies in the animal health market investigating and marketing crossover drugs

Key Reasons to Purchase

This report will allow you to -

- Gain insightful analyses and understanding of the crossover drugs market: This report describes and assesses the key differences between the human and animal healthcare markets, areas of unmet need in the veterinary market and key factors responsible for ELDU in the veterinary setting.

- Assess high-profile marketed human products used for treating animals: Our new study provides analyses of the key human therapies that have the potential to be transitioned in the veterinary space.

- Identify the most important drivers and restraints of the crossover drugs market: This report provides insights regarding what is currently driving the prescription and application of human drugs in the veterinary setting as well as the current factors restraining further transition.

- Review the key and emerging companies that market crossover drugs and the business strategies being employed: This report assesses current tactics used by top veterinary pharmaceutical companies in manufacturing and marketing cross-over drugs. It also reviews the emerging companies that manufacture cross-over drugs for various indications.

- Assess future trends in the veterinary market: This report contains our prediction for what the future holds for crossover drugs, future treatment landscapes and evolving marketing models.

Table of Contents
for Human Drugs For Veterinary Use - Current Trends and Future Commercial Prospects for Crossover Drugs

  • Table Of Contents

    Introduction

    The Human and Animal Healthcare Industries

    Human Drugs for Veterinary Use: Overview Regulations for Human Drugs Applied in Veterinary Medicine

    Regulation of Human Drugs for Veterinary Use in the US

    Extra-Label Drug Use Algorithm

    Regulation of Human Drugs for Veterinary Use in Canada

    Regulation of Human Drugs for Veterinary Use in the EU Unmet Needs and Factors Promoting Demand for Human Drugs in the Veterinary Space Human Drugs Applied in Veterinary Medicine: Case Studies

    Lysodren (Mitotane) in Dogs

    Fluoxetine hydrochloride (Prozac) in Dogs and Cats

    Benazepril (Lotensin, Fortekor) in Dogs and Cats

    Quinidine Sulfate in Horses and Dogs

    Chemotherapy in Dogs and Cats Human Drugs for Veterinary Use: Key Marketed Products

    Sildenafil

    Methimazole

    Amlodipine

    Phenobarbital

    Levothyroxine

    Acetaminophen

    Hydroxyzine

    Humulin N

    Pentoxifylline

    Bethanechol

    Human Prescription and OTC Drugs used in Dogs and Cats Factors Driving the Crossover Drugs Market Factors Restraining the Crossover Drugs Market Key Established Global Players in the Crossover Drugs Market

    Zoetis

    Boehringer Ingelheim Vetmedica

    Merck/MSD Animal Health

    Elanco (Eli Lilly)

    Merial (Sanofi)

    Bayer Animal Health Emerging Players in the Crossover Drugs Market Cost-Efficient Business Model for Veterinary Pharmaceutical Companies Business Models and Crossover Drugs: Examples and Future Focus Areas Business Strategies Employed by Animal Health Companies with Crossover Drugs Future Outlook in the Animal Health Market Bibliography

Additional Details

Publisher

CBR Pharma Insights

Publisher Information

Reference

19908 |

Number of Pages

60

Report Format

PDF

CBR Pharma Insights Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Human Papilloma Virus Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
National Human Genome Research Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryNational Human Genome Research Institute (NHGRI) a subsidiary of National Institutes of Healt...
27 Apr 2016 by Global Data USD $250 More Info
National Human Genome Research Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryNational Human Genome Research Institute (NHGRI) a subsidiary of National Institutes of Healt...
14 Mar 2016 by Global Data USD $250 More Info
Cell Isolation/Cell Separation Market by Product (Reagent, Media, Serum, Bead, Centrifuge), Cell Type (Human, Stem Cell, Animal), Technique (Filtration, Surface Marker), Application (Research, IVD) & End user (Hospital, Biotechnology) - Forecast to 2020
The global cell isolation market is expected to reach USD 6.3 billion by 2020 from USD 2.9 billion i...
11 Jan 2016 by MarketsandMarkets USD $4,650 More Info
Human Immunodeficiency Virus (HIV) - US Drug Forecast and Market Analysis to 2023
Human Immunodeficiency Virus (HIV) - US Drug Forecast and Market Analysis to 2023SummaryHuman immuno...
09 Sep 2015 by Global Data USD $4,995 More Info
Human Immunodeficiency Virus (HIV) - Japan Drug Forecast and Market Analysis to 2023
Human Immunodeficiency Virus (HIV) - Japan Drug Forecast and Market Analysis to 2023SummaryHuman imm...
09 Sep 2015 by Global Data USD $4,995 More Info
Human Immunodeficiency Virus (HIV) - 5EU Drug Forecast and Market Analysis to 2023
Human Immunodeficiency Virus (HIV) - 5EU Drug Forecast and Market Analysis to 2023SummaryHuman immun...
09 Sep 2015 by Global Data USD $6,995 More Info
Human Immunodeficiency Virus (HIV) - Brazil Drug Forecast and Market Analysis to 2023
Human Immunodeficiency Virus (HIV) - Brazil Drug Forecast and Market Analysis to 2023SummaryHuman im...
09 Sep 2015 by Global Data USD $4,995 More Info
Human Immunodeficiency Virus (HIV) - China Drug Forecast and Market Analysis to 2023
Human Immunodeficiency Virus (HIV) - China Drug Forecast and Market Analysis to 2023SummaryHuman imm...
09 Sep 2015 by Global Data USD $4,995 More Info
Human Immunodeficiency Virus (HIV) - Current and Future Players
Human Immunodeficiency Virus (HIV) - Current and Future PlayersSummaryGlobalData has released its ph...
09 Sep 2015 by Global Data USD $2,995 More Info

This report is published by CBR Pharma Insights

Download Free Report Summary PDF

Human Drugs For Veterinary Use - Current Trends and Future Commercial Prospects for Crossover Drugs | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data